Last reviewed · How we verify
NCT04894214: VICAR
Flow-controlled Ventilation (FCV) in Moderate Acute Respiratory Distress Syndrome (ARDS) Due to COVID-19
trial testing Arterial blood gas (ABG) in COVID-19 Acute Respiratory Distress Syndrome in 11 participants. Completed in 1 May 2021.
23 April 2021
Quick facts
| Lead sponsor | University Hospital, Antwerp |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 11 |
| Start date | 11 January 2021 |
| Primary completion | 23 April 2021 |
| Estimated completion | 1 May 2021 |
| Sites | 1 location across Belgium |
Drugs / interventions tested
- Arterial blood gas (ABG)
- Recording of hemodynamic monitoring
- Recording of respiratory monitoring
Conditions studied
- COVID-19 Acute Respiratory Distress Syndrome — all drugs for COVID-19 Acute Respiratory Distress Syndrome →
- Respiration, Artificial — all drugs for Respiration, Artificial →
Sponsor
University Hospital, Antwerp
Who can join
Adults 18 to 80, any sex, with COVID-19 Acute Respiratory Distress Syndrome or Respiration, Artificial. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Flow controlled ventilation (FCV) is a fairly new mode of mechanical ventilation, consisting of a constant inspiratory and expiratory flow. Inspiration is thus comparable to volume controlled ventilation (VCV). The actively controlled, constant flow during expiration is unique. FCV is known to minimize dissipated energy to the lung \[ref\] and is therefore supposed to aid in lung protective ventilation. The VICAR study is designed as a prospective single cohort crossover trial. The intervention consists of a sequence of respiratory modes: baseline pressure controlled ventilation (PCV) during 5 minutes, followed by 30 minutes of FCV with an evone respirator (Ventinova Medical B.V., Eindhoven, The Netherlands) and eventually 30 minutes of VCV. Every participant will receive the intervention. Respiratory rate (RR), positive end-expiratory pressure (PEEP) and inspiratory fraction of oxygen (FiO2) will be held constant. According to the manufacturers guidelines, an I:E ratio of 1:1 will be pursued during FCV. During FCV, the respirator will be set with the same PIP as during baseline PCV. For VCV, the same tidal volume as during baseline PCV will be set.
Publications & conference data
2 peer-reviewed publications reference this trial (live from Europe PMC):
-
Flow-controlled ventilation - a new and promising method of ventilation presented with a review of the literature.
Bialka S, Palaczynski P, Szuldrzynski K, Wichary P, et al · · 2022 · cited 14× · PMID 35142160 · DOI 10.5114/ait.2022.112889 -
Flow-controlled ventilation in moderate acute respiratory distress syndrome due to COVID-19: an open-label repeated-measures controlled trial.
Van Dessel ED, De Meyer GR, Morrison SG, Jorens PG, et al · · 2022 · cited 5× · PMID 35608696 · DOI 10.1186/s40635-022-00449-4
Verify or expand the search:
- PubMed search for NCT04894214
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Arterial blood gas (ABG)
Trials testing the same drug.
- NCT03734822 — Comparative Analysis of CO2 Monitoring Methods in Patients With CF Undergoing General Anesthesia · NA · completed
Other recruiting trials for COVID-19 Acute Respiratory Distress Syndrome
Currently open trials in the same condition.
- NCT06402318 — Passive Detection- SARS-CoV-2 (COVID-19) A&M Breathalyzer (PROTECT Kiosk) for Operational Medicine · recruiting
- NCT05765396 — SARS-CoV-2/COVID-19 Study of Next Generation Non-Invasive Passive Detection Technologies · active not recruiting
- NCT04964115 — Post Acute Sequelae of COVID-19 · active not recruiting
- NCT05164744 — Cardiac Magnetic Resonance Tissue Characterization in COVID-19 Survivors · recruiting
- NCT04896853 — Treatment of Respiratory Complications Associated With COVID19,Influenza ,Metapneumovirus,RSV Infection Using ProTrans® · Phase 1 · active not recruiting
Other University Hospital, Antwerp trials
Trials by the same sponsor.
- NCT07455422 — A Study of Barrett's Esophagus Patients: Optimization of a Risk Model to Better Predict the Development of Cancer Recurr · NA · not yet recruiting
- NCT07020715 — A Phase IIa Study of Vitamin D3 Tolerogenic Dendritic Cells (tolDC) for Multiple Sclerosis · Phase 2 · not yet recruiting
- NCT07443761 — Patients Undergoing Pancreatic Surgery at the Antwerp University Hospital. · active not recruiting
- NCT06372847 — DISE-HNS Effect Study · NA · recruiting
- NCT07189091 — CReep and Maintenance flUid Sodium Chloride ADministration rEduction in cRitically Ill adultS · Phase 4 · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04894214 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by University Hospital, Antwerp
- Last refreshed: 3 February 2022
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04894214.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing